UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of:August 2017 (Report No. 1)
Commission file number:001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name into English)
5 Azrieli Center (Square Tower)
Tel-Aviv 6702501, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
Other Events
On August 10, 2017, Therapix Biosciences Ltd. (the “Company”) issued a press release announcing its third quarter financial results and business update for the quarter ended June 30, 2017 and details of a conference call to be held at 8:30 a.m. EST on August 10, 2017 to discuss the results and business update. The press release is attached as Exhibit 99.1 and is incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
Exhibits | |
99.1 | Earnings Press Release dated August 10, 2017 |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Therapix Biosciences Ltd. (Registrant) | ||
By | /s/ Josh Blacher | |
Name: | Josh Blacher | |
Title: | Chief Financial Officer |
Date: August 10, 2017
3